Skip to content
Search

Latest Stories

SPECIAL REPORT: NE London LPC unveils its High Street Clinic model to reposition pharmacy

The North East London local pharmaceutical committee has unveiled a new model to reposition community pharmacy as an integrated care provider in the community.

Speaking at an event organised by the LPC in Ilford last month, its secretary, Hemant Patel, said the idea behind a ‘High Street Clinic’ was “to examine the possibility of what happens beyond dispensing.”


It was also to explore ways to utilise the clinical skills of community pharmacists, their public health expertise as well as maximising on “our unique and strong links to the communities that we serve.”

“High Street Clinic looked at all the challenges coming our way and how we can reposition ourselves in order to take advantage of the changes instead of protesting about it,” he told a gathering which included leading NHS figures, heads of pharmacy bodies and pharmacy contractors.

The LPC said the purpose of the high street model was not to devalue the important role of community pharmacy but to consider what else it could do to help communities take charge of their health and wellbeing.

“With very limited resources but with a lot of enthusiasm and new ideas, we have created new models of care that improve care in our patients, local communities and everything around us.” the LPC said.

In response to changes taking place within health and social care and realising that the existing support systems for LPCs were not adequate for the delivery of a new vision, they have created an award-winning provider company, FirstCare Connection, under the leadership of Janaka Perera, who’s also the Committee’s strategy lead.

Speaking at the event, he explained how the LPC’s London offer was an opportunity to get the best out of communities by leveraging community pharmacy as an asset.

“Community pharmacy, as an asset, has value to it, but it’s not recognised,” he said.

By having meaningful conversations with the public, community pharmacy could demonstrate their real value, Perera said, adding that those conversations with the public will translate into a role, which can be delivered at the PCN level.

He said the High Street Clinic model was an offer they were making to “our system leaders”.

But he added: “It’s taken a lot of work and a lot of discussion, very heated discussion, about what we can and what we can’t do – do we have the workforce, do we have the premises to do this? Is it better for the GPs to do?”

Perera’s team is preparing what he called a “suite of tools to support our contractors to develop themselves as leaders locally.” These tools, he said, will “support their engagement” with the general practice and other players within their respective PCNs and allow the contractors to have the right conversations around delivery of new services.

“The offer is also about making sure that what we put out there across North East London against all those 48 PCNs is consistent because at the end of the day what we are focussed on is patient care – it’s about their experience and about the outcomes they get from our interventions.”

The High Street Clinic model takes a leaf out of the retail-based clinics that have proliferated in the US in the past few years and aligns to meet the aims and objectives of the NHS long term plan.

The new model focuses on development of workforce and collaborative working, embracing technology, mobile health and automation, reviewing premises design and the network requirements influencing contractual mechanisms and professional regulations.

NEL LPC’s vision for community pharmacy retains and enhances the link with all communities, promotes professionalism in a collaborative environment and helps to embrace change – thereby helping reposition the sector within the health and social care economy.

Expanding on the purpose of High Street Clinic, Chairman of the LPC, Surinder Singh Kalsi, said: “With very limited resources but with a lot of enthusiasm and new ideas we have created new models of care that improve care in our patients, local communities and everything around us.

“The world of community pharmacy has been difficult and uncertain, but we also acknowledge that we have a key role to play in the new landscape and delivering and supporting health and well-being to our communities.”

Mark Lyonette, Chief Executive at the NPA said: “It was a pleasure to join an impressive number of contractors, local and national stakeholders for an interesting and stimulating evening in Ilford.  NE London LPC has long been a champion for clinical service development and they continue to think big about what community pharmacy can do.”

A group of pharmacists from the LPC, called the ‘clinical army’, has already undergone a postgraduate diploma programme in clinical pharmacy at Bath University. They will be responsible for upskilling their local pharmacy workforce.

Simon Dukes, PSNC CEO, said: “The North East London community pharmacy offer demonstrates the scope and ambition of how pharmacy can work with and for the community.  The LPC has worked hard to engender an environment where community pharmacies can come together in Primary Care Networks and work closely with GPs, other healthcare professionals and local commissioners to deliver on the CPCF and beyond."

This article also appears in the February issue of Pharmacy Business.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less